Document:

License Agreement Amendment No. 9

 Exhibit 10.5 
 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and
the omitted text has been filed separately with the Securities and Exchange Commission. 
 EXECUTION VERSION 
 LICENSE AGREEMENT 
 AMENDMENT
No. 9 
 This License Agreement Amendment No. 9 (the “Amendment No. 9”) executed and delivered as of July 24, 2009
amends the License Agreement dated September 20, 2005, as later amended (the "Agreement") by and between Standard & Poor’s Financial Services LLC (“S&P”), as assignee and successor in interest to Standard &
Poor’s Standard & Poor’s, a division of The McGraw-Hill Companies, and Chicago Mercantile Exchange Inc. (“CME”). 
 RECITALS 
 WHEREAS, S&P and CME are parties to the Agreement, and now mutually desire to
amend certain terms of the same. 
 NOW, THEREFORE, in consideration of the premises and the covenants and conditions contained herein,
the sufficiency of which is hereby acknowledged, the parties, intending to be legally bound, hereby agree as follows. All capitalized terms used but not defined in this Amendment No. 9 shall have the meaning assigned to such terms in the
Agreement. 
 1. Section 2(a) of the Agreement shall be amended by replacing the last sentence of the existing Section 2(a) with the following:

 In addition, S&P hereby further grants to CME worldwide licenses: (1) to use the S&P-GSCI Excess Return Index,
S&P-GSCI Crude Oil Excess Return Index, and S&P-GSCI Gold Excess Return Index in connection with clearing, marketing, and promoting Cleared OTC Swaps; and (2) to use and refer to the S&P-GSCI Excess Return Index, S&P-GSCI Crude
Oil Excess Return Index, and S&P-GSCI Gold Excess Return Index marks in connection with clearing, marketing, and promoting Indexed Contracts and with making such disclosures about such Cleared OTC Swap as CME deems necessary or desirable under
any applicable federal or state laws, rules or regulations or under this Agreement in order to indicate the source of the S&P Stock Indices. 
 3.
Section 5 of the Agreement shall be amended by adding the following language after Section 5(k): 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 (K) Cleared OTC Swap License Fee - Oil and Gold. In addition to all other
fees and royalties payable by CME in this Agreement, CME shall pay S&P an annual OTC payment each year for the right to clear, market and promote the Cleared OTC Swaps based on the S&P-GSCI Crude Oil Excess Return Index, and S&P-GSCI
Gold Excess Return Index. The first such payment is due sixty (60) days after execution of this Amendment No. 9. Subsequent payments shall be due on the anniversaries of this Amendment No. 9 during the Term. The payments shall be
$***** in the first year, $***** in the second and third years. Either party, in its sole discretion, may propose an adjustment of the annual payment for the Cleared OTC Swaps based on the S&P-GSCI Crude Oil Excess Return Index, and S&P-GSCI
Gold Excess Return Index by providing written notice of such at least 180 days prior to the third anniversary of this Amendment No. 9. Such adjusted payment shall apply to the remainder of the Term. The parties agree to negotiate in good faith
any proposed adjustment. If the parties do not agree on the adjustment prior to 30 days before the third anniversary, this Agreement shall terminate on the third anniversary solely with respect to the Cleared OTC Swaps based on the S&P-GSCI
Crude Oil Excess Return Index, and S&P-GSCI Gold Excess Return Index. If no such written notice is received, the payment shall remain at $***** per year for the remainder of the Term. 
  

	4.	Section 10(h) of the Agreement shall be amended by replacing the existing language with the following: 

 (h) Cleared OTC Swap Report. CME shall provide to S&P a quarterly report within thirty (30) days of the end of each
calendar quarter. The format and contents of such report shall be in CME’s sole discretion but it shall at a minimum include the number of Cleared OTC Swaps based on the S&P-GSCI Excess Return Index, S&P-GSCI Crude Oil Excess Return
Index, and S&P-GSCI Gold Excess Return Index licensed hereunder and cleared by CME during the quarter. Further, CME shall provide S&P an annual report within thirty (30) days of the end of each calendar year that includes the identities
of all parties to transactions in Cleared OTC Swaps based on the S&P-GSCI Excess Return Index, S&P-GSCI Crude Oil Excess Return Index, and S&P-GSCI Gold Excess Return Index. S&P shall treat such reports as confidential information
and shall use the annual report sole for the purpose of determining such parties’ licensed rights to participate in the Cleared OTC Swaps market at CME. 
 5. In the event of any conflict, ambiguity or inconsistency between the terms and conditions of this Amendment No. 9 and the terms and conditions of the Agreement, the terms and conditions of this Amendment No. 9 shall govern and
control. 
  

 2 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 Except as modified hereby, all of the terms and conditions of the Agreement shall remain in full force and effect.

  

 3 

 Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the
Securities and Exchange Commission. The omissions have been indicated by asterisks (“*****”), and the omitted text has been filed separately with the Securities and Exchange Commission. 
  

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 9 to be executed as of
the date specified above. 
  

									
	 STANDARD & POOR’S FINANCIAL SERVICES
LLC, assignee and successor in interest to
Standard & Poor’s, a division
of The McGraw-Hill
Companies, Inc.
	 		 	 CHICAGO MERCANTILE EXCHANGE INC.

					
	 By:
	 	 /s/ Robert Shakotko
	 		 	By:	 	 /s/ Rick Redding

					
	 Name:
	 	 Robert Shakotko
	 		 	Name:	 	Rick Redding
	 Title:
	 	 Managing Director, Index Services
	 		 	Title:	 	Managing Director Products and Services Development

  

 4Schedule of Retention Plan Awards to Named Executive Officers

 Exhibit 10.1 
 Schedule of Retention Plan Awards to Named Executive Officers 
 The following cash payments will be made to GTC’s named executive officers under the GTC Biotherapeutics 2008 Retention Incentive Plan after March 31, 2010 or upon earlier termination of their
employment by GTC. 
  

				
	 Named Executive Officer
	  	Retention Payment
to be made after
March 31, 2010
	 Geoffrey F. Cox
	  	$	94,000
	 John B. Green
	  	$	44,000
	 Harry M. Meade
	  	$	44,000
	 Richard Scotland
	  	$	44,000
	 Daniel S. Woloshen
	  	$	44,000First Amendment of the License Agreement, dated November 9, 2007

 Exhibit 10.1 
 FIRST AMENDMENT OF THE LICENSE AGREEMENT 
 The Parties
to the License Agreement of July 10, 2007 (“License Agreement”), SANGAMO BIOSCIENCES, INC., a Delaware corporation having its principal place of business at Point
Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and SIGMA-ALDRICH CO., an Illinois corporation having its principal place of business at
3050 Spruce Street, St. Louis, MO 63103, (“Sigma”), hereby amend the Agreement as follows: 
 The following Section 3.4 is added:

 3.4 Exchange of Materials 
 (a) Each Party may, from time to time, wish to supply to the other Party proprietary biological or chemical material and nucleic acid sequences (“Material”) under the terms and conditions of
this Agreement for use in the Research Plan Collaboration or in the development of ZFP Products. The supply of Material on or after the Amendment Execution Date (as defined below) shall be promptly confirmed by a writing describing the Material and
the date of its exchange in the form of Exhibit H (attached hereto). Exhibit J lists all Materials exchanged prior to the Amendment Execution Date and the date of such exchange. 
 (b) For each supply of Material (other than ZFP Products supplied by Sangamo to Sigma), the supplying Party grants to the receiving Party a
non-exclusive right to use such Material for the sole purpose of work on the Research Plan Collaboration or in development of ZFP Products. 
 (c) Each Party shall only supply Material under this Section 3.4 that is the sole property or under the control of such Party. Each Party recognizes that no license is granted or implied to such
Party with respect to the Material supplied by the other Party under this Section 3.4 unless otherwise provided in this Agreement. 
 (d) The receiving Party shall use reasonable efforts to protect Material from access by Third Parties other than its employees or consultants who are obligated to hold Material in confidence. At the
supplying Party’s option, the receiving Party shall either return to the supplying Party or destroy all remaining Material upon supplying Party’s written request. The receiving Party shall not, without the written permission of the
supplying Party, use the Material supplied hereunder as the basis for an application for a patent or other form of protection or registration covering the Material or its use. 
  

 1. 

 C. Except as amended hereby, the Agreement shall remain in full force and effect. Those amendments made
herein shall be effective retroactive to July 10, 2007. 
 IN WITNESS
WHEREOF, the Parties have executed this First Amendment of the License Agreement in duplicate originals by their proper officers as of November 9, 2007 (the “Amendment Execution Date”). 
  

									
	SANGAMO BIOSCIENCES, INC.	 		 	SIGMA-ALDRICH CO.
					
	By:	 	 /s/    David G. Ichikawa
	 		 	By:	 	 /s/    David Smoller

	Name:	 	 David G. Ichikawa
	 		 	Name:	 	 David Smoller

	Title:	 	 Sr. V.P., Business Development
	 		 	Title:	 	 President, Research Biotech

  

 2. 

 Exhibit H 
 Material Transmittal Form 
 Pursuant to Article 3.4 of the License Agreement 
 Name of company representative providing Material (print):                         
                                         
                                         
                                    
 Signature of company representative:                               
                                         
                                         
                                         
                                 
 Date that Material is provided to recipient:                          
                                         
                                         
                                         
                            
 Project reference (if available):                               
                                         
                                         
                                         
                                         
  
 DESCRIPTION OF MATERIAL: 
  

 3. 

 Exhibit J 
 Previously Transferred Materials 
 No non-ZFP proprietary materials
have been transferred between the Parties. 
  

 4.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]